Pneumococcal 20-valent conjugate vaccine - Pfizer
Alternative Names: 20vPnC; APEXXNAR; Multivalent Pneumococcal conjugate vaccine - Pfizer; PCV20; PCV20 - Pfizer; PF-06482077; Pneumococcal 20-valent Conjugate Vaccine; Pneumococcal conjugate vaccine - Pfizer; PREVENAR 20; PREVNAR 20Latest Information Update: 08 Aug 2024
At a glance
- Originator Pfizer
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
- Registered Otitis media
Most Recent Events
- 30 Jul 2024 Pfizer initiates phase II trial in Pneumococcal infections (In Infants, prevention) in the US (NCT06531538)
- 29 Jul 2024 Pfizer plans a phase II trial for Pneumococcal infections (In Infants, prevention) in the US and Puerto Rico (IM) in July 2024 (NCT06524414)
- 25 Jul 2024 Pfizer initiates a phase II trial for Pneumococcal infections (In Infants, prevention) in the US (IM) (NCT06524414)